AB0626 IMATINIB FOR THE TREATMENT OF SYSTEMIC SCLEROSIS: RATIONALE, CLINICAL EVIDENCE AND FUTURE DEVELOPMENT | Annals of the Rheumatic Diseases

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Scientific Abstracts

Abstracts Accepted for Publication

Scleroderma, myositis and related syndromes

AB0626 IMATINIB FOR THE TREATMENT OF SYSTEMIC SCLEROSIS: RATIONALE, CLINICAL EVIDENCE AND FUTURE DEVELOPMENT

Online download statistics by month:

Online download statistics by month: June 2020 to April 2023

	Abstract	Full	Pdf
Jun 2020	14	0	3
Jul 2020	6	0	1
Aug 2020	4	0	0
Sep 2020	34	0	2
Oct 2020	56	0	0
Nov 2020	12	0	0
Dec 2020	6	0	2
Jan 2021	42	0	0
Feb 2021	16	0	0
Mar 2021	18	0	1
Apr 2021	164	0	1
May 2021	30	0	1
Jun 2021	1	0	0
Jul 2021	0	0	1
Aug 2021	0	0	1
Sep 2021	1	0	1
Oct 2021	30	0	0
Nov 2021	37	0	0
Dec 2021	44	0	1
Jan 2022	26	0	2
Feb 2022	35	0	1
Mar 2022	32	0	0
Apr 2022	28	0	1
May 2022	24	0	0
Jun 2022	72	0	4
Jul 2022	24	0	0
Aug 2022	104	0	1
Sep 2022	256	0	7
Oct 2022	36	0	0
Nov 2022	40	0	0
Dec 2022	46	0	0
Jan 2023	18	0	0
Feb 2023	16	0	1
Mar 2023	21	0	1
Apr 2023	54	0	0
Total	1347	0	33